Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer

Sponsor
Ruijin Hospital
Study ID
NCT07026149
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib+Camrelizumab+SOX — DRUG
    Apatinib 250mg+Camrelizumab 200mg +S-1, Oxaliplatin, q3w
  • Preoperative Radiotherapy — RADIATION
    Radiotherapy was administered using IMPT or IMRT. The target volume includes the gastric lesion, and regional lymph nodes. A regimen of 41.4 Gy in 23 fractions is preferred.

Study Details

The study is being conducted to evaluate the efficacy, safety and tolerability of radiotherapy and chemotherapy, apatinib with camrelizumab in the neoadjuvant (prior to surgery) and adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Key Dates

Start date
Jun 8, 2025
Status verified
Jun 2025
Primary completion
Sep 1, 2025
Completion
May 31, 2030

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1
    Radiotherapy and Apatinib and Camrelizumab and S-1 and Oxaliplatin

Primary Outcome Measure

Pathological Complete Response [ Time Frame: Up to 6 weeks after completion of radiotherapy and 3 cycles (each cycle is 21 days) of neoadjuvant drug treatment ]

Central Contacts

Related Studies